These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Dornase alfa. A review of its pharmacological properties and therapeutic potential in cystic fibrosis. Bryson HM; Sorkin EM Drugs; 1994 Dec; 48(6):894-906. PubMed ID: 7533697 [TBL] [Abstract][Full Text] [Related]
10. A two-year randomized, placebo-controlled trial of dornase alfa in young patients with cystic fibrosis with mild lung function abnormalities. Quan JM; Tiddens HA; Sy JP; McKenzie SG; Montgomery MD; Robinson PJ; Wohl ME; Konstan MW; J Pediatr; 2001 Dec; 139(6):813-20. PubMed ID: 11743506 [TBL] [Abstract][Full Text] [Related]
11. Vibrating membrane devices deliver aerosols more efficient than standard devices: a study in a neonatal upper airway model. Tiemersma S; Minocchieri S; van Lingen RA; Nelle M; Devadason SG J Aerosol Med Pulm Drug Deliv; 2013 Oct; 26(5):280-6. PubMed ID: 23273244 [TBL] [Abstract][Full Text] [Related]
12. Aerosolized dornase alfa (rhDNase) for therapy of cystic fibrosis. Hodson ME Am J Respir Crit Care Med; 1995 Mar; 151(3 Pt 2):S70-4. PubMed ID: 7881698 [TBL] [Abstract][Full Text] [Related]
13. Small airway deposition of dornase alfa during exacerbations in cystic fibrosis; a randomized controlled clinical trial. Bakker EM; Volpi S; Salonini E; Müllinger B; Kroneberg P; Bakker M; Hop WC; Assael BM; Tiddens HA Pediatr Pulmonol; 2014 Feb; 49(2):154-61. PubMed ID: 23913868 [TBL] [Abstract][Full Text] [Related]
14. Physicochemical aspects and efficiency of albuterol nebulization: comparison of three aerosol types in an in vitro pediatric model. Sidler-Moix AL; Di Paolo ER; Dolci U; Berger-Gryllaki M; Cotting J; Pannatier A Respir Care; 2015 Jan; 60(1):38-46. PubMed ID: 25516995 [TBL] [Abstract][Full Text] [Related]
15. Nebuliser systems for drug delivery in cystic fibrosis. Daniels T; Mills N; Whitaker P Cochrane Database Syst Rev; 2013 Apr; (4):CD007639. PubMed ID: 23633344 [TBL] [Abstract][Full Text] [Related]
16. Aerosolized dornase alfa in cystic fibrosis: is there a role in the management of patients with early obstructive lung disease? Geller DE Pediatr Pulmonol; 1997 Aug; 24(2):155-8; discussion 159-61. PubMed ID: 9292913 [TBL] [Abstract][Full Text] [Related]
17. Nebulization of PEGylated recombinant human deoxyribonuclease I using vibrating membrane nebulizers: A technical feasibility study. Mahri S; Wilms T; Hagedorm P; Guichard MJ; Vanvarenberg K; Dumoulin M; Frijlink H; Vanbever R Eur J Pharm Sci; 2023 Oct; 189():106522. PubMed ID: 37423579 [TBL] [Abstract][Full Text] [Related]
18. A crossover, randomized, controlled trial of dornase alfa before versus after physiotherapy in cystic fibrosis. Fitzgerald DA; Hilton J; Jepson B; Smith L Pediatrics; 2005 Oct; 116(4):e549-54. PubMed ID: 16147970 [TBL] [Abstract][Full Text] [Related]
19. Is a longer time interval between recombinant human deoxyribonuclease (dornase alfa) and chest physiotherapy better? A multi-center, randomized crossover trial. Wilson CJ; Robbins LJ; Murphy JM; Chang AB Pediatr Pulmonol; 2007 Dec; 42(12):1110-6. PubMed ID: 17955550 [TBL] [Abstract][Full Text] [Related]
20. Changes in performance of the Pari eFlow rapid and Pari LC Plus during 6 months use by CF patients. Rottier BL; van Erp CJ; Sluyter TS; Heijerman HG; Frijlink HW; Boer AH J Aerosol Med Pulm Drug Deliv; 2009 Sep; 22(3):263-9. PubMed ID: 19466906 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]